EUVIMEDEUVIMED entdecken
Crossref

Dengzhan Shengmai capsule ameliorates cognitive impairment via inhibiting ER stress in APP/PS1 mice

Hui-Han Ma, Jia-Yi Zheng, Yu-Hui Qiu, Shan Su, Fang-Mei Lu, Guang-Liang Wu, Shi-Jie Zhang, Ye-Feng Cai

Journal of Ethnopharmacology · 2025-02 · 338 · 119016

DOI: 10.1016/j.jep.2024.119016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ethnopharmacology, 2025-02. Verfasst von Hui-Han Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou,…. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Endoplasmic Reticulum Stress, Mice, Transgenic, Cognitive Dysfunction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ETHNOPHARMACOLOGICAL RELEVANCE: Alzheimer's disease (AD) is a common type of neurodegenerative disease with the β-amyloid plaques (Aβ) deposition. Previously, Dengzhan Shengmai capsule (DZSM) has been shown to reduce the pathology associated with AD, but the underlying mechanism is unclear. AIM OF STUDY: This study investigated the potential mechanisms of DZSM against AD. MATERIALS AND METHODS: The six-month-old wild-type male mice and APP/PS1 double transgenic male mice were administered 0.9 % saline or DZSM for 8 weeks by gavage. Open field test, new object recognition test, and Morris Water maze test were used to assess spatial learning and memory. Aβ plaques in brains were visualized using ThT staining. Nissl staining, TUNEL staining, and Western blot analyses were used to detect the neuronal function and apoptosis level. The superoxide dismutase (SOD), glutathione peroxidase assay kit (GSH-Px), and malondialdehyde (MDA) kits were performed to assess oxidative stress levels. Then, immunofluorescence and Western blot analysis were applied to evaluate ER stress pathway protein levels. Finally, HT22 cells were treated by Aβ1-42 with or without DZSM medicated serum. Cell viability was assessed using the CCK-8 assay, and Western blot analysis was applied to evaluate ER stress pathway protein levels. RESULTS: Open filed test, new object recognition test and Morris Water maze test showed that DZSM restored cognitive disorders in APP/PS1 mice. Immunohistochemistry and Thioflavin T staining results indicated that DZSM reduced Aβ plaques in the brain. Deeper and denser Nissl bodies were found in APP/PS1 mice after DZSM administration. Besides, APP/PS1 mice treated with DZSM showed a lower level of TUNEL and Bax/Bcl-2 ratio. DZSM improved the acetylcholine (ACh), choline acetyltransferase (ChAT), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) activity while reducing acetylcholinesterase (AChE) and malondialdehyde (MDA) activity. In addition, the levels of ER stress pathway containing Phospho-PKR-like ER kinase (P-PERK), phosphorylate eukaryotic initiation factor 2 (P-eIF2α), activating transcription factor 4 (ATF4), glutamine-rich protein 1 (QRICH1), phosphorylate inositol-requiring protein 1α (P-IRE1α), the spliced form of X-box binding protein 1 (XBP1s), activating transcription factor-6 (ATF6) and C/EBP homologous binding protein (CHOP) were decreased by DZSM. CCK-8 results indicated that DZSM medicated serum played cytoprotective effects on Aβ1-42-induced HT22 cells. Western blot results suggested DZSM possibly inhibited ER stress pathways in Aβ1-42-induced HT22 cells. CONCLUSION: The potential protective mechanism of DZSM on cognitive impairment in AD might be related to ER stress pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalEndoplasmic Reticulum StressMice, TransgenicCognitive DysfunctionAlzheimer DiseaseAnimalsMaleMiceAmyloid beta-PeptidesOxidative StressPresenilin-1Amyloid beta-Protein PrecursorApoptosisDisease Models, AnimalMice, Inbred C57BLNeuroprotective AgentsBrainMaze LearningCell Line

Stichwörter der Autor:innen

Alzheimer's diseaseCognitive impairmentDengzhan Shengmai capsulesEndoplasmic reticulum stressGlutamine-rich protein 1

Substanzen

Drugs, Chinese Herbaldengzhan shengmai capsuleAmyloid beta-PeptidesPresenilin-1Amyloid beta-Protein PrecursorNeuroprotective Agents

Autor:innen und Institutionen

  • State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Department of Neurology, The Second Affiliated Hospita…
  • Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China. Electr…
  • Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.

Zitieren

APA

Ma, H. H., Zheng, J. Y., Qiu, Y. H., Su, S., Lu, F. M., Wu, G. L., Zhang, S. J., & Cai, Y. F. (2025). Dengzhan Shengmai capsule ameliorates cognitive impairment via inhibiting ER stress in APP/PS1 mice. Journal of Ethnopharmacology, 338, 119016. https://doi.org/10.1016/j.jep.2024.119016

Vancouver

Ma HH, Zheng JY, Qiu YH, Su S, Lu FM, Wu GL, et al. Dengzhan Shengmai capsule ameliorates cognitive impairment via inhibiting ER stress in APP/PS1 mice. Journal of Ethnopharmacology. 2025;338:119016. doi:10.1016/j.jep.2024.119016

BibTeX
@article{Ma2025,
  author = {Ma, Hui-Han and Zheng, Jia-Yi and Qiu, Yu-Hui and Su, Shan and Lu, Fang-Mei and Wu, Guang-Liang and Zhang, Shi-Jie and Cai, Ye-Feng},
  title = {Dengzhan Shengmai capsule ameliorates cognitive impairment via inhibiting ER stress in APP/PS1 mice},
  journal = {Journal of Ethnopharmacology},
  year = {2025},
  volume = {338},
  pages = {119016},
  doi = {10.1016/j.jep.2024.119016}
}
Kostenlos starten →